Illumina Names Charles Dadswell as Senior Vice President and General Counsel

  Illumina Names Charles Dadswell as Senior Vice President and General Counsel

    Dadswell Brings Extensive Intellectual Property Experience to Illumina
                                Executive Team

Business Wire

SAN DIEGO -- April 22, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced it has appointed Charles Dadswell
as Senior Vice President and General Counsel. Dadswell will assume all
functional responsibilities previously held by Christian Cabou, who has
retired, and will have worldwide responsibility for all legal and intellectual
property matters as well as being Secretary to Illumina’s Board of Directors.

“Chuck brings a deep understanding of the intellectual property and legal
issues facing innovative health care companies,” said Jay Flatley, President
and Chief Executive Officer of Illumina. “We are excited to welcome him to the
team and value the expertise he brings as Illumina continues to grow.”

Dadswell joins Illumina with more than 20 years of leadership and legal
experience at health care-focused technology companies. Most recently, he was
Vice President, General Counsel for North and Latin America and Corporate
Director of Global Intellectual Property at bioMerieux. In this role, he was
responsible for global intellectual property matters and legal matters in
North and Latin America. Prior to bioMerieux, he was General Counsel of
BioDelivery Sciences International, a specialty pharmaceutical company; and
oversaw US intellectual property in a variety of positions with Glaxo,
GlaxoWellcome and GlaxoSmithKline. Dadswell holds a LLM in patent law and
trade regulation from The George Washington University Law School, a JD from
the Thomas M. Cooley Law School and a bachelor’s in science from Ferris State
University.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.